IXICO plc - IXICO to Present at HD and Ataxia Conferences

RNS Number : 1955S
05 November 2019

5 November 2019                                                                                                                                           



("IXICO" or the "Company")


IXICO to Present Abstracts at Upcoming Huntington's Disease and Ataxia Conferences


IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, today announces that it is scheduled to attend and present scientific posters at the following conferences in November 2019.

The Huntington Study Group 2019 Annual Meeting

7 - 9 November 2019, Sacramento, California, USA   

IXICO will present a poster entitled "A Fully Automatic Pipeline for Estimation of Putamen and Caudate Volume" on 7 November at 5pm and on 8 November at 3.15pm.

The abstract outlines a method for fully automated segmentation of the caudate and putamen brain structures using IXICO's proprietary LEAP™ algorithm technology as applied to a Huntington disease cohort.

In addition, IXICO is supporting the event as 'Friends of HSG' and the company's biomarker scientist, Dr Kirsi Kinnunen, will be participating in the 'Ask the Expert' panel for the HSG Family Day on Saturday 9th November.

International Ataxia Research Conference 2019

14 - 16 November 2019, Washington DC, USA

IXICO will present an abstract entitled "Fully automated measurement of brainstem and cerebellar volume: imaging endpoint for Ataxia, PSP and FA in multicenterclinical trial studies" on 14 November at 5.30pm and on 15 November at 12.30pm in Exhibit Hall A.

The abstract describes the scientific validation of a fully-automated volumetric assessment of cerebellar and brainstem regions as well as operational considerations for successful deployment in clinical trials.

Giulio Cerroni, Chief Executive Officer of IXICO commented: "We are delighted to be presenting abstracts on some of our pioneering data analytics at these upcoming conferences.  As new therapies for neurodegenerative diseases enter clinical development, the improvement and validation of image analysis pipelines using AI technologies, such as LEAP™, can critically support trial design and clinical investigation."

Poster authors:

HSG: Richard Joules1, Helen Crawford1, Robin Wolz1, 2 1) IXICO plc, London, UK 2) Imperial College London, London, UK

IARC: Abaei M1*, Joules R1, Palombit A1, Faber J2, 3, Klockgether T2, 3, Wolz R1, 4

1) IXICO Plc, London, UK, 2) DZNE, German Center for Neurodegenerative Diseases, Bonn Germany, 3) Department of Neurology, University Hospital Bonn, Germany4 Department of Computing, Imperial College London, London, UK, *Presenting author




For further information please contact:



+44 (0) 20 3763 7498

Giulio Cerroni, Chief Executive Officer




Optimum Strategic Communications

 +44 (0) 203 950 9144

Mary Clark / Supriya Mathur / Charlotte Hepburne-Scott


[email protected]






IXICO's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience and rare disease. 

Our goal is to be a leading proponent in the use of AI in clinical development, to improve biopharma R&D productivity through the adoption of breakthrough data analytics in precision healthcare. Through the deployment of novel AI algorithms, we analyse and interpret brain scans and digital biosensor data to enable better trial design, patient selection and ultimately clinical outcomes across all phases of clinical evaluation. Our data analytics services are deployed on some of the most important clinical trials in neuroscience and rare disease, providing valuable insights to disease progression and patient safety, enabling our clients to make better informed decisions earlier in the clinical development pathway.

More information is available on www.IXICO.com


About HSG Annual Meeting 2019


Since 1993, the Huntington Study Group (HSG) has hosted an annual, internationally recognized forum for training and education of Huntington disease (HD) researchers and for presentation of new research findings and treatments to the worldwide community.  The event brings together more than 600 of the world's leading Huntington disease researchers, health care providers, industry representatives, and members of the HD community, providing an opportunity for researchers to share abstracts of their efforts to help improve the lives for people affected by Huntington disease.


About IARC 2019


The International Ataxia Research Conference (IARC) provides a comprehensive scientific review of new research into ataxias, covering topics from the molecular basis of disease to potential therapeutic treatments and clinical trials. The conference includes Friedreich's ataxia and other recessive ataxias (e.g. ataxia with oculomotor apraxia), dominant ataxias (e.g. spinocerebellar ataxias, DRPLA, episodic ataxias) and autoimmune ataxias. The meeting is aimed at academic, clinical and industry researchers with an interest in ataxia research and drug development.   

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Quick facts: IXICO PLC

Price: 83

Market: AIM
Market Cap: £39.09 m

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


IXICO CEO 'delighted' with stronger than anticipated second half growth

IXICO PLC's (LON:IXI) Giulio Cerroni caught up with Proactive London's Katie Pilbeam after announcing they've raised earnings expectations for the current fiscal year. He says revenues for the year to the end of September 2020 will be in line with, or slightly ahead of, current market...

on 24/8/20